Mark Simon Purchases 11,061 Shares of Cabaletta Bio (NASDAQ:CABA) Stock

Cabaletta Bio, Inc. (NASDAQ:CABA) Director Mark Simon acquired 11,061 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were bought at an average price of $2.28 per share, for a total transaction of $25,219.08. Following the completion of the purchase, the director owned 147,205 shares in the company, valued at $335,627.40. This trade represents a 8.12% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cabaletta Bio Stock Up 25.6%

Shares of NASDAQ CABA opened at $2.94 on Friday. The company has a market cap of $283.00 million, a P/E ratio of -1.16 and a beta of 3.25. Cabaletta Bio, Inc. has a 52 week low of $0.99 and a 52 week high of $3.67. The business has a 50-day simple moving average of $2.30 and a two-hundred day simple moving average of $2.12.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.05. Equities research analysts anticipate that Cabaletta Bio, Inc. will post -2.34 EPS for the current year.

Institutional Investors Weigh In On Cabaletta Bio

Several hedge funds have recently added to or reduced their stakes in the company. Bain Capital Life Sciences Investors LLC boosted its holdings in shares of Cabaletta Bio by 250.5% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 9,677,125 shares of the company’s stock worth $14,709,000 after purchasing an additional 6,916,237 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Cabaletta Bio by 142.9% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock valued at $13,421,000 after buying an additional 5,195,285 shares in the last quarter. Jennison Associates LLC lifted its position in Cabaletta Bio by 147.4% in the 2nd quarter. Jennison Associates LLC now owns 6,020,167 shares of the company’s stock worth $9,151,000 after buying an additional 3,586,439 shares during the last quarter. Vanguard Group Inc. boosted its stake in Cabaletta Bio by 21.4% in the third quarter. Vanguard Group Inc. now owns 4,190,759 shares of the company’s stock worth $9,806,000 after buying an additional 740,032 shares in the last quarter. Finally, Woodline Partners LP boosted its stake in Cabaletta Bio by 75.2% in the third quarter. Woodline Partners LP now owns 2,135,348 shares of the company’s stock worth $4,997,000 after buying an additional 916,884 shares in the last quarter.

Trending Headlines about Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: CEO Steven Nichtberger purchased 45,000 shares at an average ~$2.24, increasing his stake to ~1.03M shares — a sizable insider buy from the company’s top executive. Read More.
• Positive Sentiment: Multiple other insiders (director Mark Simon, director Shawn Tomasello, insiders Steve Gavel, Gwendolyn Binder, David J. Chang, and General Counsel Michael Gerard) executed material purchases at ~$2.19–$2.28 per share — broad insider participation that signals management/board conviction. Read More.
• Positive Sentiment: Unusually large options activity: investors bought ~3,428 CABA call options (an ~83% increase vs. average daily call volume), consistent with short‑term bullish speculative interest.
• Positive Sentiment: Company program update coverage: reports say Cabaletta is accelerating its autoimmune CAAR‑T program and is targeting a 2027 FDA filing — a clear development roadmap that could materially de‑risk value if milestones are met. Read More.
• Neutral Sentiment: Analyst coverage remains skewed positive on the longer term (consensus “Moderate Buy” with an average price target well above current levels), but those price targets reflect successful clinical progress and are not guarantees. Read More.
• Neutral Sentiment: Institutional ownership moves reported previously show larger biotech investors increasing stakes — supportive for liquidity, but not an immediate catalyst.

Analysts Set New Price Targets

Several brokerages have commented on CABA. Cantor Fitzgerald raised their price target on shares of Cabaletta Bio from $15.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Jefferies Financial Group assumed coverage on Cabaletta Bio in a research report on Friday, October 10th. They issued a “buy” rating and a $14.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Cabaletta Bio in a research report on Friday, October 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Wednesday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.25.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.